Synthesis and antitumor evaluation of glycyrrhetinic acid‐dithiocarbamate hybrids

Abstract

Glycyrrhetinic acid (GA) is a naturally occurring triterpene compound. The aim of this study was to employ the pharmacophore hybrid strategy to merge GA with various dithiocarbamates and obtain novel compounds with better antitumor activities. We present a two‐step synthetic protocol wherein the GA derivative underwent reaction with carbon disulfide and various secondary amines in a one‐pot manner under mild conditions, facilitating the preparation of a series of structurally novel GA‐dithiocarbamate derivatives. Bioassay screening revealed that the representative compound 3c demonstrated the capacity to reduce the mitochondrial membrane potential in Hep3B and Huh‐7 cells, induce nuclear apoptosis, inhibit invasion and migration, and prompt both early and late apoptosis. Furthermore, our research findings indicated that this apoptotic phenomenon may be associated with the expression of Bcl‐2, Bax, Bak, PARP, and cleaved‐PARP proteins. Utilizing network pharmacology for predicting core targets and signaling pathways of compound 3c for hepatocellular carcinoma (HCC) treatment involved employing molecular docking models to demonstrate high affinity between compound and target protein. In conjunction with Western blot analysis, compound 3c may impact HCC through the PI3K‐AKT‐mTOR pathway.